Introduction

Gefitinib is a molecular-targeted and orally active agent that inhibits epidermal growth factor receptor (EGFR) tyrosine kinase and exhibits antitumor activity for advanced non-small cell lung cancer (NSCLC). Interstitial lung disease (ILD) is a severe side effect of gefitinib therapy. According to a 2004 report by AstraZeneca showing the results of a prospective investigation of the adverse events associated with gefitinib therapy, the incidence of gefitinibinduced ILD was 6.47%, and 38.6% of these cases were fatal. Despite the clinical significance of gefitinib-induced ILD, the mechanism underlying its pathogenesis remains unclear.
We hypothesized that oxidative stress is involved in the pathogenesis of gefitinib-induced ILD because it is one of the common factors that cause drug-associated ILD (1) (5) , rheumatoid arthritis (6) , heart failure (7), exacerbation of asthma (8) , and acute respiratory distress syndrome (ARDS) (9) 
Patients and Methods
Patient profile and treatment
This
Measurement of serum Trx levels
Serum Trx levels were measured by an enzyme-linked immunosorbent assay (ELISA) as previously reported (10) . The values were corrected with the hemoglobin concentrations in the same serum samples to exclude the contribution by Trx derived from red blood cells (11) .
Results
Elevation of serum thioredoxin in patients with gefitinib-induced ILD
Forty-four patients were entered into this study (Table 1) . There were three cases (3/44, 6 Fig. 1A-C (Fig. 1D) .
.8%) of gefitinib-induced ILD (Table 2) and all of their pulmonary infiltrations improved gradually after cessation of gefitinib therapy with (patients A and B) or without (patient C) administration of T a b l e 2 . P r o f i l e o f P a t i e n t s wh o Un d e r we n t Ge f i t i n i b -I n d u c e d I L D
PSL. Temporal changes of serum Trx levels in the patients are shown in
. The levels on the day of detection of the infiltration showed significant elevation, compared with those on day 1 (p=0.023, paired t-test). They decreased after cessation of gefitinib therapy. In patients without ILD, serum Trx levels showed no significant elevation in any period during treatment, compared with those on day 1
Comparison of Trx levels on day 1 between patients with and without ILD
To determine whether serum Trx levels can be a predictive marker of incidence of ILD, we compared serum Trx levels on day 1 between two subgroups with and without ILD. They were statistically comparable (Fig. 2) , showing that the serum Trx levels at the beginning of gefitinib therapy are not predictive of the incidence of gefitinib-induced ILD.
Discussion
Previous reports have shown that the serum Trx level is a good indicator of oxidative stress (2-9). The present study suggests one possibility that oxidative stress may be involved in the mechanisms causing or worsening gefitinibinduced ILD. Many anti-cancer agents such as bleomycin, adriamycin, and cisplatin exhibit their anti-tumor effects at least in part by producing reactive oxygen species (ROS). Trx is expressed in bleomycin-injured pulmonary epithelial cells (12). Trx is induced by oxidative stress and secreted from the cells. Trx may be secreted from lungs injured by gefitinib-induced oxidative stress and that the serum Trx level fluctuates reflecting the activity of ILD. However, it is considered that the main pharmacological effect of gefitinib is not directly related to oxidative stress (13). Further study is needed to clarify the mechanism how oxidative stress is generated in gefitinib-induced ILD.
We showed that the serum Trx level is not predictive of the incidence of ILD. In many patients, the serum Trx levels were high at the beginning of gefitinib treatment. Cellular redox status is involved in the growth promotion of cancer cells (14) . The serum Trx levels are elevated in patients with pancreatic cancer (2) or hepatocellular carcinoma (15) . Advanced lung cancer may be involved in the high Trx levels. (17) , and brain injury during brain ischemia/ reperfusion (18) . Intratracheal instillation of diesel exhaust particles (DEP) induced the generation of ROS in the lung, which was attenuated in Trx-transgenic mice (19) . Some extracellular Trx enters cells and also inhibits ROS production (20) . Recombinant Trx protein exerts anti-oxidant effects against DEP-induced oxidative stress in A549 culture cells (19) . Intravenous injection of recombinant Trx suppresses the infiltration of leukocyte into the inflammatory site (21) . Trx administration attenuates bleomycin-induced ILD and inflammatory cytokine-induced interstitial pneumonia (16 
F i g u r e 1 . ( A-C) T e mp o r a l c h a n g e s o f s e r u m T r x l e v e l s i n t h r e e p a t i e n t s wh o h a d g e f i t i n i b -i nd u c e d I L D. T h e d a y o f c e s s a t i o n o f g e f i t i n i b t r e a t me n t i s s h o wn b y a n a r r o w. Co mp a r i s o n b e t we e n t h e l e v e l o n d a y 1 a n d t h a t o n t h e d a y o f c e s s a t i o n ( * ) s h o ws s i g n i f i c a n t d i f f e r e n c e ( p = 0 . 0 2 3 , p a i r e d t -t e s t ) ( D) T e mp o r a l c h a n g e s o f s e r u m T r x l e v e l s i n p a t i e n t s t r e a t e d wi t h g e f i t i n i b wi t h o u t I L D. Me a n l e v e l s ± o n e s t a n d a r d d e v i a t i o n o n d a y 1 a n d f o l l o wi n g e i g h t p e r i o d s a r e s h o wn . Co mp a r e d wi t h t h e l e v e l s o n d a y 1 , t h e o t h e r l e v e l s i n e a c h o f t h e e i g h t p e r i o d s a r e n o t s i g n i f i c a n t l y d i f f e r e n t ( p a i r e d t -t e s t ) . T r x : t h i o r e d o x i n
F i g u r e 2 . S e r u m T r x l e v e l s i n p a t i e n t s wi t h a n d wi t h o u t g e f i t i n i b -i n d u c e d I L D o n d a y 1 . ( p = 0 . 4 3 , Ma n n -Wh i t n e y t e s t ) . I L D: i n t e r s t i t i a l l u n g d i s e a s e , T r x : t h i o r e d o x i n
